A combined STD-NMR/molecular modeling protocol for predicting the binding modes of the glycosidase inhibitors kifunensine and salacinol to Golgi alpha-mannosidase II.
A combined STD-NMR/molecular modeling protocol to probe the binding modes of the glycosidase inhibitors kifunensine and salacinol to Drosophila melanogaster Golgi alpha-mannosidase II (dGMII) was tested. Saturation-transfer difference (STD) NMR experiments were carried out for the complexes of dGMII with these two inhibitors. The program AutoDock 3.0 was then used to optimize the interactions of the inhibitors with the residues in the active site of dGMII. Theoretical STD effects of the ligand protons in the complexes were calculated for the different binding modes with the recently developed CORCEMA-ST protocol. Comparison of experimental and theoretical effects then permitted selection of the likely binding modes of the ligands. The more rigid kifunensine was used initially to test the protocol. Excellent correlation between experimental and theoretical data was obtained for one of the binding modes that also corresponded to that observed in the crystal structure of the complex. The protocol was then extended to the more flexible salacinol. For the selected binding mode, good correlation of experimental and theoretical data for the five-membered ring was obtained; however, poor correlation for protons on the acyclic chain was obtained, suggesting flexibility in this portion of the molecule. Comparison of the selected binding mode with that from a crystal structure of salacinol with dGMII showed excellent superimposition of the five-membered ring but another orientation of the acyclic chain. The results suggest that reliable structural binding modes of a ligand to protein in aqueous solution can be provided with the combined use of STD-NMR spectroscopy, molecular modeling, and CORCEMA-ST calculations, although highly flexible portions of the ligand may be poorly defined.
Wen
Xin
X
Department of Chemistry, Simon Fraser University, Burnaby, British Columbia, Canada V5A 1S6.
Yuan
Yue
Y
Kuntz
Douglas A
DA
Rose
David R
DR
Pinto
B Mario
BM
D000470:Alkaloids / Q000737:chemistry* / Q000378:metabolism; D000818:Animals; D001665:Binding Sites; D003198:Computer Simulation; D004331:Drosophila melanogaster / Q000201:enzymology; D004791:Enzyme Inhibitors / Q000737:chemistry* / Q000378:metabolism; D006056:Golgi Apparatus / Q000201:enzymology*; D019476:Insect Proteins / Q000737:chemistry / Q000378:metabolism; D008024:Ligands; D046911:Macromolecular Substances / Q000737:chemistry / Q000378:metabolism; D008361:Mannosidases / Q000037:antagonists & inhibitors* / Q000737:chemistry* / Q000378:metabolism; D008956:Models, Chemical; D008958:Models, Molecular; D019906:Nuclear Magnetic Resonance, Biomolecular / Q000379:methods*; D011237:Predictive Value of Tests; D011487:Protein Conformation; D013402:Sugar Alcohols / Q000737:chemistry* / Q000378:metabolism; D013431:Sulfates / Q000737:chemistry* / Q000378:metabolism; D013816:Thermodynamics; D043323:alpha-Mannosidase / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000378:metabolism
D000470:Alkaloids; D004791:Enzyme Inhibitors; D019476:Insect Proteins; D008024:Ligands; D046911:Macromolecular Substances; D013402:Sugar Alcohols; D013431:Sulfates; C427963:salacinol; C065629:kifunensine; D008361:Mannosidases; C038829:mannosyl-oligosaccharide 1,3 - 1,6-alpha-mannosidase; D043323:alpha-Mannosidase